https://biotechpharmainvestor.substack.comhttps://x.com/StmkrsBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical background helps me evaluate the scientific fundamentals of biotech stocks.Due to seeking alpha rules and time constraints I cannot cover here all stocks that I am following/trading. I write about such stocks in substack and XAnalyst’s Disclosure: I/we have a beneficial ...

In short: SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with les ...

ATLANTA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Inovio’s business, operations, and prospects, including allegations that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 Biologi ...

Core Insights - Crown Holdings, Inc. specializes in metal packaging production, competing with major players like Ball Corporation and Ardagh Group, with a strong presence in the beverage can and North American tinplate markets [1][6] Financial Performance - UBS set a price target of $126 for Crown Holdings, indicating an 11.62% potential increase from the current trading price of $112.88 [2][6] - The company reported a record adjusted EBITDA of approximately $2.1 billion for 2025, reflecting an 8% increase from the previous year, with a 20% growth over the past three years [2][3][6] - Crown Holdings generated a record free cash flow of $1.15 billion in 2025, accumulating nearly $2 billion over the past two years, supporting its market position and future growth potential [4] Business Strategy - The company's strategic focus on continuous improvement and capacity expansions has significantly contributed to its financial success, with segment income from global beverage can and North American tinplate businesses expanding by over 8% in 2025 [3] - Consistent performance is evident with growth rates of 6% and 7% in 2024 and 2023, respectively [3] Stock Performance - Despite positive financial results, Crown Holdings' stock price has experienced fluctuations, currently trading at $112.88, with a slight decrease of approximately -1.16% today [5] - Over the past year, the stock has seen a high of $115.85 and a low of $75.98, indicating volatility in its performance [5]

The State Street Consumer Staples Select Sector SPDR ETF (NYSEARCA:XLP) and the Fidelity MSCI Consumer Staples Index ETF (NYSEARCA:FSTA) both target U.S. consumer staples, but XLP is much larger and pays a higher yield, while FSTA offers broader diversification and slightly lower volatility. Both XLP and FSTA are designed to give investors exposure to the U.S. consumer staples sector, focusing on companies that provide essential products like food, household goods, and personal care items. This comparison ...

Webster Financial Corporation (NYSE:WBS) operates as a commercial bank across the Northeast, focusing on commercial banking, healthcare financial services, and consumer banking. ...

The AppLovin logo arranged on a laptop in New York on Feb. 26, 2025.Short-seller CapitalWatch has issued an apology and revised its report accusing a major AppLovin shareholder of financial crimes. The report, published last month, alleged relationships between Hao Tang and criminal syndicates, which the short-seller now says is inaccurate."Descriptions asserting direct connections between Mr. Tang and Chen Zhi, Prince Group, Jin Bei Group, Tang Jun, and Yang Zhihui were inaccurate and failed to meet our pu ...

MILWAUKEE, Feb. 9, 2026 /PRNewswire/ -- Ademi LLP is investigating Valaris (NYSE: VAL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Transocean. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Valaris stockholders will receive 15.235 shares of Transocean stock for each Valaris share. Upo ...

Eli Lilly (NYSE: LLY) stock bounced back 2.4% by 9:50 a.m. ET Monday after taking a tumble last week. Shares of the big pharma stock and manufacturer of Mounjaro and Zepbound GLP-1 weight loss drugs sank several percent Thursday after Hims & Hers Health (NYSE: HIMS) announced it would sell an Ozempic lookalike pill to compete with Novo Nordisk's (NYSE: NVO) Wegovy pill -- and with Eli Lilly's Mounjaro and Zepbound injectable weight loss drugs as well. Will AI create the world's first trillionaire? Our team ...

MUNCIE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- First Merchants Corporation, a $21.4 billion financial holding company, announced that Larry Myers has been appointed to the Boards of Directors of First Merchants Corporation and First Merchants Bank. Myers recently announced plans to transition from his role as President and Chief Executive Officer of First Savings Bank and First Savings Financial Group, Inc., positions he has held for nearly 20 years. The two organizations completed their merger on February ...